A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.
Lind, Michael J Gomm, S Simmonds, A P Ashcroft, Linda Kamthan, A Gurney, H Thatcher, Nick
Lind, Michael J
Gomm, S
Simmonds, A P
Ashcroft, Linda
Kamthan, A
Gurney, H
Thatcher, Nick
Citations
Altmetric:
Abstract
A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.
Description
Date
1991
Publisher
Collections
Keywords
Lung Cancer
Type
Article
Citation
A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer. 1991, 28 (2):142-4 Cancer Chemother Pharmacol